Abstract
Tirzepatide is a dual-action glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 (GLP-1) receptor agonist and the first drug in a new class known as twincretins. It is similar to GLP-1 receptor agonists but provides a synergistic enhancement of the incretin effect to control blood glucose levels and reduce weight. Across the SURPASS research program trials, tirzepatide lowered A1C by 1.7–2.4% from baseline. The proportion of patients using tirzepatide who achieved an A1C
| Original language | English |
|---|---|
| Pages (from-to) | 367-377 |
| Number of pages | 11 |
| Journal | Clin. Diabetes |
| Volume | 41 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2023 |
Keywords
- glucose
- hemoglobin A1c
- high density lipoprotein cholesterol
- insulin
- insulin degludec
- insulin glargine
- low density lipoprotein cholesterol
- metformin
- semaglutide
- sulfonylurea
- tirzepatide
- twincretin
- unclassified drug
- abdominal pain
- acute disease
- Article
- body mass
- body weight loss
- cardiovascular mortality
- cerebrovascular accident
- constipation
- decreased appetite
- diabetic retinopathy
- diarrhea
- diastolic blood pressure
- dyspepsia
- gallbladder disease
- glycemic control
- heart infarction
- hospitalization
- human
- hypoglycemia
- monotherapy
- multicenter study (topic)
- nausea
- non insulin dependent diabetes mellitus
- pancreatitis
- phase 3 clinical trial (topic)
- stomach paresis
- systolic blood pressure
- unstable angina pectoris
- vomiting